REG - Genus - Directorate Change

GenusAnnouncement

23/08/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230823:nRSW2168Ka&default-theme=true

RNS Number : 2168K  Genus PLC  23 August 2023

For Immediate Release

23 August 2023

Genus plc

Non-Executive Director Retirement

Genus plc (LSE: GNS), a leading global animal genetics company, announces that
Lykele van der Broek, Non-Executive Director, has informed the Company of his
intention to step down from the Genus Board, effective from the conclusion of
the 2023 Annual General Meeting on 22 November 2023, after nine years' service
as a Non-Executive Director.

Russell Reynolds has been retained and is in the process of identifying
potential successors for Lykele.

Commenting on the retirement, Iain Ferguson, Chairman of Genus, said:

"On behalf of the Board I want to acknowledge Lykele's significant
contributions to the Board's deliberations, bringing to the fore his
experience and knowledge as a leader in growing agricultural businesses across
global markets. We thank him for his contributions, we will miss his keen
insight and business acumen during our Board discussions and wish him well for
the future."

For further information please contact:

Genus:

Iain Ferguson,
Chairman
Tel: +44 (0)1256 345970

Jorgen Kokke, Chief Executive

 Buchanan:

Charles Ryland /Chris Lane/ Verity
Parker                           Tel: +44 (0)207 466
5000

About Genus

Genus creates advances to animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming and food
producers. Its technology is applicable across livestock species and is
currently commercialised by Genus in the dairy, beef and pork food production
sectors.

 

Genus' worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

 

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGIGDIBDDDGXX